| Biomarker ID | 1484 |
| PMID | 25075250 |
| Year | 2014 |
| Biomarker | miR-219 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in Metastatis (No Metastasis: 0.532 ± 0.028; Metastatis: 0.448 ± 0.029) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: nucleoplasm; positive regulation of metabolic process; positive regulation of cellular metabolic process; DNA-binding transcription factor activity, RNA polymerase II-specific; anatomical structure morphogenesis |
| Experiment | Metastatic Vs Non Metastatic Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | 215 samples were chosen for analysis. 204 were malignant and 11 were benign. 111 without metastatis and 80 with metastatis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p= 0.039 |
| Method Used | In Situ hybridization (ISH) |
| Clinical | No |
| Remarks | Results for epithelial carcinoma cell study |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |